Skip to main content
TuHURA Biosciences, Inc./NV logo

TuHURA Biosciences, Inc./NV — Investor Relations & Filings

Ticker · HURA ISIN · US49720K1016 LEI · 549300J5YAIKFR65J029 US Professional, scientific and technical activities
Filings indexed 899 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country US United States of America
Listing US HURA

About TuHURA Biosciences, Inc./NV

https://tuhurabio.com/

TuHURA Biosciences, Inc. is a Phase 3 clinical-stage immuno-oncology company that develops novel therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company's pipeline is based on three distinct technology platforms: IMMUNE FX (IFX), an innate immune agonist; TBS-2025; and Bi-Specific Immune Modulating Antibody Drug Conjugates (ADCs). Its lead product candidate, IFX-2.0, is in a Phase 3 registration trial for patients with advanced melanoma who are resistant to checkpoint inhibitors.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-29 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K
Regulatory Filings
2026-05-15 English
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
Regulatory Filings
2026-04-22 English
424B5 - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
Regulatory Filings
2026-04-08 English
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
Regulatory Filings
2026-04-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.